Recent Advances in the Treatment of Obesity

Speaker(s)

• 

  Ania Jastreboff, MD, PhD

  Associate Professor of Medicine, Endocrinology & Metabolism
  Yale University School of Medicine

  Disclosure(s): Boehringer Ingelheim: Consultant (Ongoing)
  Eli Lilly: Consultant (Ongoing); Grant/Research Support (Ongoing)
  Intellihealth: Consultant (Ongoing)
  Novo Nordisk: Consultant (Ongoing); Grant/Research Support (Ongoing)
  Novo Nordisk AS: Consultant (Ongoing)
  Pfizer: Consultant (Ongoing)
  Rhythm Pharmaceuticals: Consultant (Ongoing); Grant/Research Support (Ongoing)
  Scholar Rock: Consultant (Ongoing)
  WWF International: Consultant (Ongoing)
• 

  John Buse, MD, PhD

  Verne S. Caviness Distinguished Professor; Chief, Division of Endocrinology
  University of North Carolina School of Medicine

  Disclosure(s): Alkahest: Consultant (Ongoing)
  Altimmune: Consultant (Ongoing)
  Anji: Consultant (Ongoing)
  AstraZeneca: Consultant (Ongoing)
  Bayer: Consultant (Ongoing)
  Biomea Fusion Inc: Consultant (Ongoing)
  Boehringer-Ingelheim: Consultant (Ongoing)
  CeQur: Consultant (Ongoing)
  Cirius Therapeutics Inc: Consultant (Ongoing)
  Dexcom: Grant/Research Support (Ongoing)
  Eli Lilly and Co.: Consultant (Ongoing)
  GentiBio: Consultant (Ongoing)
  Glycadia: Consultant (Ongoing)
  Glyscend: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
  Janssen: Consultant (Ongoing)
  LipoScience: Consultant (Ongoing)
  MannKind: Consultant (Ongoing)
  Medtronic: Grant/Research Support (Ongoing)
  Mellitus Health: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
  Moderna: Consultant (Ongoing)
  NovaTarg: Grant/Research Support (Ongoing)
  Novo Nordisk: Consultant (Ongoing); Grant/Research Support (Ongoing)
  Pendulum Therapeutics: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
  PhaseBio: Stock Shareholder (excluding mutual funds) (Ongoing)
  Praetego: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
  Sanofi Aventis: Grant/Research Support (Ongoing)
  Stability Health: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
  Tolerion: Grant/Research Support (Ongoing)
  Valo: Consultant (Ongoing)
  vTv Therapeutics: Grant/Research Support (Ongoing)
  Zealand Pharma: Consultant (Ongoing)

Moderator(s)

• 

  Richard Kahn, PhD

  Department of Medicine
  University of North Carolina, Chapel Hill

  Disclosure(s): Abbott: Consultant (Ongoing)

This 90-minute event will review current options for the pharmacological treatment of obesity and describe the concomitant role of diet counseling and lifestyle interventions with new obesity therapies. Content will delve into the biological basis of obesity including the role of hormones on appetite and energy regulation, metabolic adaptation to weight loss, and cardiometabolic risk factors.

Target Audience: Physicians, dietitians, physician assistants, nurse practitioners, academic faculty, medical students, residents, and obesity and nutrition researchers.

Presentations:

• 1:00 PM – 1:40 PM ET

  Anti-obesity Pharmacotherapy: The Future Is Now!
  

  Speaker: Ania Jastreboff, MD, PhD – Yale University School of Medicine
• 1:40 PM – 2:00 PM ET

  GLP-1 Receptor Agonists for Obesity: Personal and Professional Perspectives
  

  Speaker: John Buse, MD, PhD – University of North Carolina School of Medicine
• 2:00 PM – 2:30 PM ET

  Panel Discussion - Recent Advances in the Treatment of Obesity
  

  Speaker: Ania Jastreboff, MD, PhD – Yale University School of Medicine

  Speaker: John Buse, MD, PhD – University of North Carolina School of Medicine

  Moderator: Richard Kahn, PhD – University of North Carolina, Chapel Hill